Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -11.74% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -30.10% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.60% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 89.28% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Cytosorbents | 25.72 Mn | 20.92 Mn | 6.13 Mn | -246.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -246.79% |
| Dec 31, 2025 | 27.36% |
| Sep 30, 2025 | -14.52% |
| Jun 30, 2025 | 145.34% |
| Mar 31, 2025 | 76.74% |
| Dec 31, 2024 | -29.69% |
| Sep 30, 2024 | 69.89% |
| Jun 30, 2024 | 30.21% |
| Mar 31, 2024 | 13.21% |
| Dec 31, 2023 | -661.61% |
| Sep 30, 2023 | 24.65% |
| Jun 30, 2023 | 43.44% |
| Mar 31, 2023 | 18.30% |
| Dec 31, 2022 | 91.77% |
| Sep 30, 2022 | -90.45% |
| Jun 30, 2022 | -132.58% |
| Mar 31, 2022 | -115.13% |
| Dec 31, 2021 | -1,273.27% |
| Sep 30, 2021 | -662.90% |
| Jun 30, 2021 | -63.15% |